
IDEXX Laboratories (IDXX) Stock Forecast & Price Target
IDEXX Laboratories (IDXX) Analyst Ratings
Bulls say
IDEXX Laboratories has achieved a remarkable customer retention rate of approximately 97%, which enhances the predictability of its revenue and earnings streams. The company has demonstrated strong growth potential with a 16% compound annual growth rate (CAGR) in organic consumables recurring revenue from 2016 to 2022, indicating robust demand for its diagnostic products and services. Additionally, customers utilizing IDEXX's full suite of offerings experience 3.5 times higher growth across various categories of testing, further supporting the company's favorable growth trajectory in the pet healthcare market.
Bears say
IDEXX Laboratories has experienced a concerning trend in clinical vet visits, which declined by 1.7% year-over-year in the fourth quarter of 2025, indicating a potential ongoing weakening in demand for its diagnostic products and services. This decline in pet patient visits, coupled with an expected further decrease of 200 basis points in pet visits in 2026, primarily attributed to economic pressures on lower-income pet owners, raises significant concerns about slower adoption of IDEXX's product portfolio. Additionally, economic downturns could impact both customers and suppliers, potentially leading to decreased demand for IDEXX's offerings and hampering revenue growth amidst these challenging market conditions.
This aggregate rating is based on analysts' research of IDEXX Laboratories and is not a guaranteed prediction by Public.com or investment advice.
IDEXX Laboratories (IDXX) Analyst Forecast & Price Prediction
Start investing in IDEXX Laboratories (IDXX)
Order type
Buy in
Order amount
Est. shares
0 shares